Fecal microbiota transplantation for the treatment of intestinal diseases after allogeneic hematopoietic stem cell transplantation in children

Cover Page

Cite item

Full Text

Abstract

Fecal microbiota transplantation (FMT) is a promising therapy for a variety of diseases involving the gastrointestinal (GI) tract. The purpose of our study is to evaluate the effectiveness of FMT for the treatment of different GI complications after allogenic hematopoietic stem cell transplantation (steroid-refractory and steroid-dependent graft versus host disease (SR/ SD GVHD) and infectious enterocolitis) in children from 1.5 to 18 years old. The study was approved by the Local Ethics Committee of the Morozov Children's Clinical Hospital of the Department of Health of Moscow (No. 176 dated 24.05.2022). The patients' parents gave their informed consent to the participation of their children in the study and the publication of the study results. SR/SD GVHD group included 14 patients and GI infections group – 11 patients. In total, 38 FMTs were performed. Eleven children underwent repeated FMTs due to the lack of effect after the first FMT. The resolution of diarrhea followed by the withdrawal of corticosteroids was recorded in 11 out of 14 patients with SR/SD GVHD. Ten out of 11 patients with GI infections also achieved relief of diarrhea. The clinical effect correlated with changes in the microbiome structure: for both groups of patients, the median proportion of normal microbiota before FMT was 6%, after FMT – 92% (p = 0.043). The median number of different taxa for both groups of patients before and after FMT were 3 and 10 taxa, respectively (p = 0.0016).

About the authors

G. Z. Seregin

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Author for correspondence.
Email: jorggg@mail.ru
ORCID iD: 0000-0003-3880-4402

Georgy Z. Seregin, a pediatric oncologist at the Department of Bone Marrow and Hematopoietic Stem Cell Transplantation 

1/9 4th Dobryninsky lane, Moscow 119049, Russia

 

Russian Federation

Yu. A. Bespyatykh

Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency

Email: juliabes@rcpcm.org
ORCID iD: 0000-0002-4408-503X

Moscow

Russian Federation

A. V. Gospodarik

Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency

Email: alina.gospodaryk@rcpcm.org
ORCID iD: 0009-0003-7870-1106

Moscow

Russian Federation

M. Yu. Kirillov

LLC DNA-Technology TS

Email: kirillov@dna-technology.ru
ORCID iD: 0009-0005-5578-4492

Moscow

Russian Federation

L. V. Ogneva

LLC DNA-Technology TS

Email: ogneva@dna-technology.ru
ORCID iD: 0009-0000-0547-4393

Moscow

Russian Federation

S. V. Zhilina

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Email: svzhilin@mail.ru
ORCID iD: 0000-0003-0084-1013

Moscow

Russian Federation

E. A. Burtsev

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Email: EBurtsev@morozdgkb.ru
ORCID iD: 0000-0002-3623-6547

Moscow

Russian Federation

A. E. Burya

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Email: ABurya@morozdgkb.ru
ORCID iD: 0000-0003-4170-7152

Moscow

Russian Federation

I. O. Vlasova

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Email: Taishikhina@morozdgkb.ru
ORCID iD: 0000-0002-9209-7238

Moscow

Russian Federation

M. R. Zhuravel

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0009-0000-2875-8372

Moscow

Russian Federation

E. A. Zhuravel

Morozov Children's Clinical Hospital of the Department of Health of Moscow

Email: EGuravel@morozdgkb.ru
ORCID iD: 0000-0003-2049-897X

Moscow

Russian Federation

V. V. Konstantinova

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0000-0002-2652-8642

Moscow

Russian Federation

B. M. Kurmanov

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0009-0003-5256-1715

Moscow

Russian Federation

A. V. Lifshits

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0000-0001-9095-1771

Moscow

Russian Federation

M. V. Natrusova

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0000-0003-4244-7110

Moscow

Russian Federation

A. E. Donnikov

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of Ministry of Health of Russian Federation

ORCID iD: 0000-0003-3504-2406

Moscow

Russian Federation

M. A. Maschan

Morozov Children's Clinical Hospital of the Department of Health of Moscow;
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0003-1735-0093

Moscow

Russian Federation

G. O. Bronin

Morozov Children's Clinical Hospital of the Department of Health of Moscow

ORCID iD: 0000-0002-0694-3996

Moscow

Russian Federation

References

  1. Cammarota G., Ianiro G., Tilg H., Rajilic-Stojanovic M., Kump P., Satokari R., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66 (4): 569–80.
  2. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium diffi e infections. Am J Gastroenterol 2013; 108 (4): 478–98.
  3. Debast S.B., Bauer M.P., Kuijper E.J.; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1–26.
  4. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. [Electronic resource] URL: https://www. fda.g o v / r e g u latory-informat i o n / search-fda-guidance-documents/enforcement-policy-regarding-inves-tigational-new-drug-requirements-use-fecal-microbiota (accessed 25.04.2024).
  5. Samet A., Sledzinska A., Krawczyk B., Hellmann A., Nowicki S., Kur J., et al. Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream. Eur J Clin Microbiol Infect Dis 2013; 32 (11): 1393–400.
  6. Maschan M., Shelikhova L., Ilushina M., Kurnikova E., Boyakova E., Balashov D., et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant 2016; 51 (5): 668–74.
  7. Kim S.B., Min Y.H., Cheong J.W., Kim J.S., Kim S.J., Ku N.S., et al. Incidence and risk factors for carbapenemand multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis 2014; 46 (2): 81–8.
  8. Caselli D., Cesaro S., Ziino O., Zanazzo G., Manicone R., Livadiotti S., et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010; 95 (9): 1612–5.
  9. Battipaglia G., Malard F., Rubio M.T., Ruggeri A., Mamez A.C., Brissot E., et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica 2019; 104 (8): 1682–8.
  10. Bilinski J., Grzesiowski P., Sorensen N., Madry K., Muszynski J., Robak K., et al. Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clin Infect Dis 2017; 65 (3): 364–70.
  11. DeFilipp Z., Peled J.U., Li S., Mahabamunuge J., Dagher Z., Slingerland A.E., et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2018; 2 (7): 745–53.
  12. Zhao Y., Li X., Zhou Y., Gao J., Jiao Y., Zhu B., et al. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial. Front Immunol 2021; 12: 678476.
  13. Goloshchapov O.V., Chukhlovin A.B., Bakin E.A., Stanevich O.V., Klementeva R.V., Shcherbakov A.A., et al. Fecal microbiota transplantation for graft-versus-host disease in childrenand adults: methods, clinical effects, safety. Therapeutic Archive. 2020; 92 (7): 43–54. (In Russ.) doi: 10.26442/00403660.2020.07.0 00773
  14. Zeiser R., Blazar B.R. Acute Graftversus-Host Disease-Biologic Process, Prevention, and Therapy. N Engl J Med 2017; 377: 2167–79.
  15. Ferrara J.L.M., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550–61.
  16. Dignan F.L., Clark A., Amrolia P., Cornish J., Jackson G.S., Mahendra P., et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158: 30–45.
  17. Andermann T.M., Peled J.U., Ho C., Reddy P., Riches M., Storb R., et al. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol. Blood Marrow Transpl 2018; 24: 1322–40.
  18. Schluter J., Peled J., Taylor B.P., Markey K.A., Smith J.A., Taur Y., et al. The gut microbiota is associated with immune cell dynamics in humans. Nature 2020; 588: 303–7.
  19. Zama D., Bossù G., Leardini D., Muratore E., Biagi E., Prete A., et al. Insights into the role of intestinal microbiota in hematopoietic stemcell transplantation. Ther Adv Hematol 2020; 11: 2040620719896961.
  20. Peled J.U., Gomes A.L., Devlin S.M., Littmann E.R., Taur Y., Sung A.D., et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med 2020; 382: 822–34.
  21. Jenq R.R., Taur Y., Devlin S.M., Ponce D.M., Goldberg J.D., Ahr K.F., et al. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biol Blood Marrow Transpl 2015; 21: 1373–83.
  22. Yoshioka K., Kakihana K., Doki N., Ohashi K. Gut microbiota and acute graft-versus-host disease. Pharmacol Res 2017; 122: 90–5.
  23. Shouval R., Geva M., Nagler A., Youngster I. Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease. Clin Hematol Int 2019; 1: 28.
  24. Cammarota G., Ianiro G., Tilg H., Rajilić-Stojanović M., Kump P., Satokari R., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–80.
  25. Wardill H.R., Secombe K.R., Bryant R.V., Hazenberg M.D., Costello S.P. Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. EBioMedicine 2019; 44: 730–40.
  26. DeFilipp Z., Bloom P.P., Soto M.T., Mansour M.K., Sater M.R., Huntley M.H., et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med 2019; 381: 2043–50.
  27. Carreras E., Dufour C., Mohty M., Kröger N. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer International Publishing AG: Cham, Switzerland; 2019.
  28. Pession A., Zama D., Muratore E., Leardini D., Gori D., Guaraldi F., et al. Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review. J Pers Med 2021; 11 (2): 100.
  29. Malard F., Huang X.J., Sim J.P.Y. Treatment and unmet needs in steroid-refractory acute graft-versushost disease. Leukemia 2020; 34 (5): 1229–40.
  30. Господарик А.В., Прохорова Н.Д., Беспятых Ю.А. Подбор доноров для трансплантации фекальной микробиоты: невольный скрининг здоровья населения. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ 2024; 10 (1): 92–103. [Gospodaryk A.V., Prokhorova N.D., Bespyatykh J.A. Selection of donors for fecal microbiota transplantation: compulsory public health screening. Healthcare Management: News, Views, Education. Bulletin of VSHOUZ 2024; 10 (1): 92–103. (In Russ.)].
  31. Zhgun E.S., Sorokina E.A., Kislun Yu.V., Ilyina E.N., Denisova E.A., Bespyatykh Yu.A. Method of obtaining freeze-dried feces preparation for fecal microbiota transplantation. A patent for invention RU 2809736 C2, 15.12.2023. The application dated 09.12.2021. (In Russ.).
  32. Voroshilina E.S., Moskvina M.V., Kirillov M.Yu., Ogneva L.V., Donnikov A.E., Itani T.M., et al. Fundamentals of modern approaches to assessing gut microbiota in children. Neonatology: news, opinions, training 2023; 11 (3): 47–59. (In Russ.).
  33. Bespyatykh J.A., Gospodarik A.V., Zhuravel E.A., Seregin G.Z., Komarova A.V., Esiev S.S., et al. Fecal Microbiota Transplantation in the Treatment of Astrovirus Infection in а Recipient of an Allogeneic Hematopoietic Stem Cell Transplant: a Clinical Case. Journal of Clinical Practice 2023; 14 (1): 115–22. (In Russ.).
  34. Ianiro G., Masucci L., Quaranta G., Simonelli C., Lopetuso L.R., Sanguinetti M., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018; 48 (2): 152–9.
  35. Akinshina A.I., Smirnova D.V., Zagainova A.V., Makarov V.V., Yudin S.M. Prospects of Using Microbiota Correction Methods in the Treatment of Infl ory Bowel Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 29 (2): 12–22. (In Russ.).
  36. Scherbakov P.L., Belova N. D., Generozov E. V., Zhgun E.S., Ivanova O.I., Ilyina E.N., et al. Faecal Transplant in GIT Treatment (Pilot Clinical Experience). Doctor.Ru 2019; 3 (158): 40–6. (In Russ.).
  37. Woodworth M.H., Carpentieri C., Sitchenko K.L., Kraft C.S. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes 2017; 8 (3): 225–37.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Seregin G.Z., Bespyatykh Y.A., Gospodarik A.V., Kirillov M.Y., Ogneva L.V., Zhilina S.V., Burtsev E.A., Burya A.E., Vlasova I.O., Zhuravel M.R., Zhuravel E.A., Konstantinova V.V., Kurmanov B.M., Lifshits A.V., Natrusova M.V., Donnikov A.E., Maschan M.A., Bronin G.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.